70 Participants Needed

IPH5201 + Durvalumab + Chemotherapy for Lung Cancer

Recruiting at 32 trial locations
IP
Overseen ByInnate Pharma
Stay on Your Current MedsYou can continue your current medications while participating
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

What is the purpose of this trial?

The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot take any other chemotherapy, investigational drugs, or immunosuppressive medications during the study.

What data supports the effectiveness of the drug combination IPH5201, Durvalumab, and chemotherapy for lung cancer?

Research shows that Durvalumab, when used alone or with chemotherapy, improves survival in non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). It is particularly effective as a maintenance therapy after chemoradiotherapy in NSCLC and has shown significant survival benefits in combination with chemotherapy in SCLC.12345

Is the combination of IPH5201, Durvalumab, and chemotherapy generally safe for humans?

Durvalumab, a part of this treatment, has been shown to have a manageable safety profile in lung cancer patients, but it can cause immune-related side effects like pneumonitis (lung inflammation), which can be serious. About 25% of patients in a study experienced immune-related side effects, with 3.4% having severe reactions.12678

What makes the drug combination of IPH5201, Durvalumab, and chemotherapy unique for lung cancer?

This treatment combines Durvalumab, an immune checkpoint inhibitor that blocks PD-L1 to help the immune system attack cancer cells, with IPH5201, a novel antibody targeting CD39, and standard chemotherapy. This combination aims to enhance the immune response against lung cancer, potentially offering a new approach for patients who may not respond well to existing treatments.124910

Eligibility Criteria

This trial is for patients with early-stage (II to IIIA) non-small cell lung cancer that can be surgically removed. They must have proper organ function, not be pregnant, and agree to use contraception. Excluded are those with small-cell lung cancer, certain genetic mutations, autoimmune diseases, another primary malignancy, or severe cardiovascular disease.

Inclusion Criteria

You are expected to live for at least 12 more weeks.
I am using birth control during the study period.
My organs and bone marrow are working well.
See 8 more

Exclusion Criteria

I have not received a live vaccine in the last 30 days.
I have previously been given durvalumab or IPH5201 in this study.
Participation in another clinical study with an investigational product administered within 30 days prior to enrolment
See 23 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Neoadjuvant Treatment

Participants receive neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy before surgery

16 weeks
Multiple visits for treatment administration

Surgery

Participants undergo surgical resection

1 week
1 visit for surgery

Adjuvant Treatment

Participants receive adjuvant treatment with IPH5201 and durvalumab post-surgery

Up to 4 months
Multiple visits for treatment administration

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 2 years
Regular follow-up visits

Treatment Details

Interventions

  • Durvalumab
  • IPH5201
  • Standard Chemotherapy
Trial OverviewThe study tests the combination of IPH5201 and durvalumab with standard chemotherapy before surgery (neoadjuvant therapy), followed by the same drugs after surgery (adjuvant therapy). It aims to evaluate safety and effectiveness in untreated NSCLC patients eligible for tumor removal.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: IPH5201 + durvalumab + standard chemotherapyExperimental Treatment1 Intervention
Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy. Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab.

Durvalumab is already approved in European Union, United States, Japan for the following indications:

🇪🇺
Approved in European Union as Imfinzi for:
  • Locally advanced, unresectable non-small cell lung cancer (NSCLC)
🇺🇸
Approved in United States as Imfinzi for:
  • Extensive-stage small cell lung cancer (ES-SCLC)
  • Limited-stage small cell lung cancer (LS-SCLC)
  • Locally advanced or metastatic urothelial carcinoma
🇯🇵
Approved in Japan as Imfinzi for:
  • Not specified in provided sources

Find a Clinic Near You

Who Is Running the Clinical Trial?

Innate Pharma

Lead Sponsor

Trials
29
Recruited
3,100+

Findings from Research

Durvalumab, a PD-L1 blocking antibody, has shown clinical efficacy and a manageable safety profile in treating advanced non-small-cell lung cancer, especially in patients with ≥25% PD-L1 expression.
The drug is being evaluated in various treatment settings, including as a monotherapy and in combination with other therapies, showing promising results particularly after chemoradiation, although lower response rates were noted in patients with EGFR and ALK mutations.
Durvalumab in non-small-cell lung cancer patients: current developments.Mezquita, L., Planchard, D.[2018]
Immune checkpoint inhibitors (ICIs), particularly durvalumab, have significantly improved treatment outcomes for patients with advanced non-small cell lung cancer (NSCLC), establishing them as the standard of care either alone or with chemotherapy.
Durvalumab is specifically approved as a consolidation treatment after chemo-radiotherapy for stage III NSCLC, highlighting its role in enhancing patient prognosis.
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context.Gullapalli, S., Remon, J., Hendriks, LEL., et al.[2020]
In the phase 3 POSEIDON study involving 1013 treatment-naïve patients with metastatic non-small-cell lung cancer (NSCLC), the combination of tremelimumab, durvalumab, and chemotherapy significantly improved overall survival and progression-free survival compared to chemotherapy alone.
Patients receiving the combination treatment also experienced a longer time to deterioration in quality of life and various symptoms, indicating better overall health status compared to those on chemotherapy, supporting its use as a first-line treatment option.
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).Garon, EB., Cho, BC., Luft, A., et al.[2023]

References

Durvalumab in non-small-cell lung cancer patients: current developments. [2018]
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context. [2020]
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). [2023]
Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer. [2022]
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. [2021]
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. [2022]
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors. [2022]
Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab. [2022]
Durvalumab: A Review in Extensive-Stage SCLC. [2022]
Durvalumab for the treatment of non-small cell lung cancer. [2019]